Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.35 USD | +7.00% | +1.52% | -5.49% |
Financials (USD)
Sales 2024 * | 7.62M | Sales 2025 * | 6.43M | Capitalization | 253M |
---|---|---|---|---|---|
Net income 2024 * | -139M | Net income 2025 * | -161M | EV / Sales 2024 * | 17.2 x |
Net cash position 2024 * | 122M | Net cash position 2025 * | 171M | EV / Sales 2025 * | 12.6 x |
P/E ratio 2024 * |
-2.23
x | P/E ratio 2025 * |
-2.36
x | Employees | 130 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.12% |
Latest transcript on Monte Rosa Therapeutics, Inc.
1 day | +1.01% | ||
1 week | -11.97% | ||
Current month | -6.02% | ||
1 month | -30.65% | ||
3 months | +5.04% | ||
6 months | +46.63% | ||
Current year | -11.50% |
Managers | Title | Age | Since |
---|---|---|---|
Markus Warmuth
CEO | Chief Executive Officer | 53 | 19-12-31 |
Chief Operating Officer | - | 21-02-28 | |
Filip Janku
CTO | Chief Tech/Sci/R&D Officer | 50 | 21-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Schiff
CHM | Chairman | 58 | 20-08-31 |
Christine Siu
BRD | Director/Board Member | 47 | 20-11-30 |
Chandra Paul Leo
BRD | Director/Board Member | 53 | 20-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - | |
0.00% | 9 M€ | +9.94% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-15 | 5.34 | +6.80% | 44 880 |
24-05-14 | 5 | +1.01% | 80,678 |
24-05-13 | 4.95 | +2.06% | 260,248 |
24-05-10 | 4.85 | -6.37% | 150,312 |
24-05-09 | 5.18 | -1.52% | 241,170 |
Delayed Quote Nasdaq, May 14, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.50% | 253M | |
+29.03% | 49.18B | |
-0.10% | 42.11B | |
+49.22% | 40.37B | |
-5.26% | 28.85B | |
+11.48% | 26.09B | |
-22.74% | 18.71B | |
+9.06% | 13.26B | |
+30.01% | 12.32B | |
-1.51% | 11.99B |
- Stock Market
- Equities
- GLUE Stock